Caffeine May Enhance NSAID-Induced Effects on Colon Cancer Cells

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 7
Volume 6
Issue 7

WASHINGTON--Laboratory studies from Rockefeller University, presented at Digestive Disease Week, suggest that caffeine may have a synergistic effect with NSAIDs in preventing the growth of cancer cells.

WASHINGTON--Laboratory studies from Rockefeller University, presentedat Digestive Disease Week, suggest that caffeine may have a synergisticeffect with NSAIDs in preventing the growth of cancer cells.

At a press briefing, Yael Goldberg, MD, said that laboratory tests haveshown that NSAIDs have an antiproliferative effect on colon cancer cellsas well as the capacity to interfere with the cell cycle and induce apoptosis.And among the cells that do not die, about 90% arrest in the cell cycle,she said.

Working in the laboratory of Dr. Steven Shiff, Dr. Goldberg and hercolleagues treated colon cancer cells with different agents in an attempt,she said, "to look more closely at the mechanism responsible for theantineoplastic effect of NSAIDs, and to think about practical ways to treatpatients."

The researcher treated HT-29 colon adenocarcinoma cells and U-2 OS osteosarcomacells for 72 hours with either a control medium alone or a control mediumsupplemented with indomethacin (400 µM), sulindac (1,200 µM),sulindac sulfide (175 µM), or caffeine (4 µM), or co-supplementedwith caffeine and one of each of the NSAIDs.

In both HT-29 and U-2 OS cells, caffeine treatment alone profoundlyinhibited proliferation but did not induce apoptosis.

Co-treatment with caffeine and one of the NSAIDs reduced proliferationmore than did treatment with any of the agents used alone. When used incombination, caffeine significantly enhanced NSAID-induced apoptosis, andalso altered cell cycle distribution and levels of several key proteinsthat likely modulate the NSAID-induced cell cycle arrest.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content